First Case of Peroxisomal D-bifunctional Protein Deficiency with Novel HSD17B4 Mutations and Progressive Neuropathy in Korea

Eun Young Bae 1, Yoonyoung Yi 1,2, Han Hyuk Lim 1, Jiwon M. Lee 1, Bongjin Lee 1,3, Seung Yeon Kim 4 and Yoo-Mi Kim 1,5

1Department of Pediatrics, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, Korea
2Department of Pediatrics, College of Medicine, Hallym University, Kangdong Sacred Heart Hospital, Seoul, Korea
3Department of Emergency Medicine, Seoul National University Hospital, Seoul, Korea
4Department of Pediatrics, Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea
5Department of Pediatrics, Chungnam National University College of Medicine, Chungnam National University Sejong Hospital, Sejong, Korea

ABSTRACT

Peroxisomal D-bifunctional protein (DBP), encoded by the HSD17B4 gene, catalyzes β-oxidation of very long chain fatty acids (VLCFAs). The deficiency of this peroxisomal enzyme leads to the accumulation of VLCFAs, causing multisystemic manifestations including the brain, retina, adrenal gland, hearing, and skeletal system. Herein, we report the first Korean neonatal case of peroxisomal DBP deficiency and the clinical prognosis over 2 years. This patient showed craniofacial dysmorphism, club foot, and seizures with cyanosis one day after birth. Elevated VLCFAs levels were indicative of a peroxisomal disorder. Targeted exome sequencing was performed and two missense mutations p.Asp117Val and p.Phe279Ser in the HSD17B4 gene were identified. The patient had type III DBP deficiency; therefore, docosahexaenoic acid and non-soluble vitamins were administered. However, progressive nystagmus, optic nerve atrophy, and bilateral hearing defects were observed and follow-up brain imaging revealed leukodystrophy and brain atrophy. Multiple anti-epileptic drugs were required to control the seizures. Over two years, the patient achieved normal growth with home ventilation and tube feeding. Hereby, the subject's parents had support during the second pregnancy from the proven molecular information. Moreover, targeted exome sequencing is an effective diagnostic approach, considering genetic heterogeneity of Zellweger spectrum disorders.

Keywords: Neonate; Hypotonia; Peroxisomal Disorder; HSD17B4

INTRODUCTION

Peroxisomal D-bifunctional protein (DBP), encoded by the HSD17B4 gene, is a peroxisomal enzyme consisting of a hydratase and hydroxyacyl-CoA dehydrogenase (HAD), and catalyzes β-oxidation of very long chain fatty acids (VLCFAs). DBP deficiency (MIM #261515) is a rare autosomal recessive Zellweger spectrum disorder (ZSD) caused by biallelic mutations.
in HSD17B4 located on chromosome 5q23.1, and leads to the accumulation of VLCFAs and deficiency of plasminogen. DBP deficiency shares resemblance with clinical features of Zellweger syndrome namely growth failure, neonatal onset encephalopathy, polyneuropathy, hearing and visual impairment, hepatomegaly, and early death in infancy. Because peroxisomes are present in all cells and play an important role in cellular functions, including fatty acid oxidation, and phospholipid and bile acid synthesis, patients exhibit clinical and genetic heterogeneity. An estimated prevalence of ZSDs and DBP deficiency is 1 in 30,000 and 1 in 100,000, respectively. Although patients can be categorized into the neonatal, juvenile, and adult onset DBP deficiency, the onset of symptoms is often in the neonatal period, and present hypotonia (98%) and seizures (93%) in the first month of life.

Targeted exome sequencing has been an effective diagnostic tool owing to genetic and clinical heterogeneity of ZSDs. To date, 83 mutations in HSD17B4 have been reported (April 2019, http://www.hgmd.cf.ac.uk), including 51 missense/nonsense, 10 small indels, 1 gross deletions, 1 gross insertions/duplications, and one rearrangement. DBP deficiency can be classified into 3 types based on the relative impairment of the enzymes activities. Type I is a deficiency of both hydratase and HAD units, type II is an isolated hydratase deficiency, and type III is an isolated HAD deficiency. Type I, II, and III represent 27%, 28%, and 45% of the cases, respectively, and exhibited poor prognosis with a mean age at death of 6.9, 10.7, and 17.6 months, respectively. Type I patients had deletion, insertion, and nonsense mutations, most type II patients had missense or in-frame mutations in the hydratase domain, and type III patients had mutations in the dehydrogenase domain. Recently, Type IV patients presented a missense mutation in each enzyme domain resulting in markedly reduced but detectable hydratase and HAD activities.

Herein, we report the first Korean neonatal onset DBP deficiency patient with compound heterozygous novel missense mutations in HSD17B4 detected by targeted exome sequencing, and patient’s multidisciplinary management for over 2 years.

**CASE DESCRIPTION**

A 28-day-old girl, the first child from non-consanguineous parents, was referred to our hospital owing to hypotonia, neonatal seizure, and elevated serum VLCFAs levels in March 19, 2018. She was born through vaginal delivery at 38+2 weeks, weighed 2.21 kg, and exhibited generalized hypotonia and feeding difficulty at birth and seizure with desaturated oxygen level one day after birth. Although her newborn screening test including tandem MS/MS was normal, metabolic evaluation for neonatal seizure revealed elevated VLCFA levels: C26:0 was 11.47 μmol/L (normal range < 1.31 μmol/L); C24:0/C22:0 was 2.21 (normal range < 1.39), and C26:0/C22:0 was 0.5 (normal range < 0.023) (Table 1). The phytanic and pristanic acid levels at 15 days of age was not detectable. On physical examination, this subject had a high forehead, large anterior fontanel, midfacial hypoplasia, high-arched palate, low-set ear, and clubfoot (Fig. 1). Thus, ZSD was suspected and targeted exome sequencing was performed for several candidate genes. The compound heterozygous mutations c.350A>T (p.Asp117Val) and c.836T>C (p.Phe279Ser), located in representative of 3-hydroxyacyl-CoA dehydrogenase deficiency in HSD17B4 (NM_000414.3) (Fig. 2A and B), were identified and inherited from the mother and father, respectively (Fig. 2C). The allele frequency of c.350A>T was 0.000109 in East Asian and c.836T>C have not reported yet (https://gnomad.broadinstitute.org/). These variants were predicted pathogenic variants by in-silico analysis using PolyPhen-2, Sorting...
Intolerant From Tolerant, and MutationTaster and classified as likely pathogenic. Although we could not perform the enzyme analysis for 3-HAD and 2-enoyl-CoA hydratase, we assessed the patient as a type III DBP deficiency through the genotype of *HSD17B4* (Fig. 2D).

She received a tracheostomy for mechanical ventilation at 35 days of age. Docosahexaenoic acid (DHA) therapy was initiated (100 mg/kg/day), and non-soluble vitamins (A, E, and D) were supplemented. Her adrenal function was normal. The clubfoot was corrected by cast followed by splint application for three months. At 1 month of age, the auditory brainstem response audiometry was performed, and the threshold was 40 dB and 60 dB in the right and left ear, respectively; however, follow-up at 6 months of age showed 90 dB and no response in the right and left ear, respectively. At 2 months of age, the ophthalmologic exam was not specific; however, she showed no eye contact and had paroxysmal asymmetric down beat nystagmus. At 18 months of age, no response to the light reflex in both eyes, optic atrophy, and retinal dystrophy was observed. At 3 days of age, the brain magnetic resonance imaging (MRI) showed the polymicrogyria at bilateral frontal and sylvian area and subependymal cyst at both caudothalamic groove (Fig. 3A and B). The follow-up brain MRI, at 18 months of age, revealed the diffuse atrophy of the cerebral hemispheres, midbrain, and cerebellum and consequent dilatation of third and lateral ventricles (Fig. 3C and D). Moreover, leukodystrophy including diffuse increased T2 signal intensity of bilateral posterior limb of internal capsule, thalami, periventricular white matter, dentate nucleus, corticospinal tract, pons, and relatively sparing subcortical white matter was noted (Fig. 3). She required multiple antiepileptic drugs including clonazepam, zonisamide, phenobarbital, and valproic acid. At one month of age, EEG revealed slow and disorganized background rhythms and frequent runs of repetitive generalized sharp and slow wave discharges, which were more
prominent in the right inferior frontal areas. At 12 months of age, EGG showed slow and disorganized background rhythms and frequent multifocal epileptiform discharges.

At 19 months of age, she showed recurrent syndrome of inappropriate antidiuretic hormone secretion (SIADH) which required admission. The serum sodium level decreased to 118 mmEq/L. Urine and serum osmolality was 396 and 247 mOsmol/kg, respectively. The urine sodium, potassium, and chloride concentration was 99.5, 22.4, and 100.1 mEq/L, respectively. The thyroid function test remained normal (thyroid stimulating hormone 1.2 µIU/mL, free T4 0.76 ng/dL). The adrenocorticotropic hormone (ACTH) stimulation test indicated high ACTH (681–760.5 pg/mL) and normal cortisol (19.79–23.29 µg/dL) levels. Thus, hydrocortisone therapy was initiated (8 mg/m²/day). The aldosterone and renin levels were 10.2 ng/dL (normal range, 3.5–24 ng/dL) and 17.3 ng/mL/hr (normal range, 0.3–1.8 ng/mL/hr), respectively.
Our patient’s parents had a second baby and were referred to another institution for prenatal genetic testing. The results from chorionic villus sampling revealed the p.Phe279Ser mutation (Fig. 2C). This subject was regularly followed-up in an outpatient clinic although the development did not improve. At 25 months of age, her height, weight, and head circumference was 85.4 cm (75–90th/p), 11.6 kg (75–90th/p), and 47 cm (50–75th/p), respectively. The serum level of C26:0 seemed to increase with age (Table 1). Home ventilation and gastric tube feeding was continued, and no cholestasis was noted.

**Ethics statement**
The patient's parents provided written informed consent for publication of the patient and family information.

**DISCUSSION**

Since first described by Watkins et al. in 1989, there have been very few reports about DBP deficiency and its management. Our patient was brought to the medical attention due to generalized hypotonia, clubfoot, and craniofacial dysmorphism at birth. Although chromosome microarray is considered a first-tier test for such symptoms, metabolic work-up including serum VLCFAs must be included for distinguishing the inborn error metabolism.
which show a facial dysmorphism and neurologic progression. Recently, VLCFAs have been introduced in the newborn screening for detecting X-linked adrenoleukodystrophy (ALD) and other peroxisomal disorders because early-detected X-linked ALD patients can be treated with hematopoietic stem cell transplantation (HSCT), besides cortisol, for progressive brain involvement at early stages. For early-detected DBP deficiency patients, the efficacy of HSCT as a treatment option for preventing neurologic deterioration must be assessed, although, to date, there are no reports about HSCT in patients with DBP deficiency.

DBP is also involved in \( \beta \)-oxidation of long-chain polyunsaturated fatty acids, important substrates for DHA biosynthesis, therefore, its deficiency leads to DHA deficiency which affects the brain and retina. Although DHA supplementation can increase DHA levels, it cannot improve clinical outcome in patients with DHA deficiency. Our patient also showed progressive visual impairment and deteriorating brain despite of early DHA supplementation (within one month).

Recent reports showed early diagnosis of children with DBP deficiency using clinical exome sequencing despite their ambiguous manifestations. Genotypes including missense, nonsense, or deletion mutations and locations of exon could help predict the prognosis of the patient. Our patient had missense mutations located in exons 6 and 12 and the DBP type III phenotype. Since exons 1 to 12 in the \( DBP \) gene encode 3-HAD and exons 13 to 19 2-enoyl-CoA hydratase, the deficient enzyme could be predicted using genetic analysis (Fig. 2D). All patients presented similar clinical manifestations regardless of their genotype, however, their life span differed. Almost all infants with DBP type I could not survive for more than one year, whereas patients with DBP types II and III often survived for 10 years. Our patients also survived for two years and required the multidisciplinary support.

We reported the first Korean neonatal onset DBP deficiency with novel mutations in \( HSD17B4 \) and clinical course over 2 years. Our case provided not only the molecular and clinical characteristics of the rare DBP deficiency but also its clinical courses supported by multidisciplinary management, providing evidence that international consensus of ultimate and preventive management for patients with DBP deficiency is warranted.

**ACKNOWLEDGMENTS**

We thank the patient and her family for their participation in this study. We greatly appreciate the Department of Medical Genetics in Asan Medical Center for providing the prenatal testing of this patient's parents.

**REFERENCES**

1. Ferdinandusse S, Denis S, Mooyer PA, Dekker C, Duran M, Soorani-Lunsing RJ, et al. Clinical and biochemical spectrum of D-bifunctional protein deficiency. *Ann Neurol* 2006;59(1):92-104.

2. Ferdinandusse S, Ylianttila MS, Gloerich J, Koski MK, Oostheim W, Waterham HR, et al. Mutational spectrum of D-bifunctional protein deficiency and structure-based genotype-phenotype analysis. *Am J Hum Genet* 2006;78(1):112-24.
3. Wanders RJ. Peroxisomal disorders: Improved laboratory diagnosis, new defects and the complicated route to treatment. Mol Cell Probes 2018;40:60-9. [PubMed | CrossRef]

4. Amor DJ, Marsh AP, Storey E, T ankard R, Gillies G, Delatycki MB, et al. Heterozygous mutations in HSD17B4 cause juvenile peroxisomal D-bifunctional protein deficiency. Neurol Genet 2016;2(6):e114. [PubMed | CrossRef]

5. Watkins PA, Harris CJ, Hoefler G, Hoefler S, Blake DC Jr, et al. Peroxisomal bifunctional enzyme deficiency. J Clin Invest 1989;83(3):771-7. [PubMed | CrossRef]

6. Nascimento J, Mota C, Lacerda L, Pacheco S, Chorão R, Martins E, et al. D-bifunctional protein deficiency: a cause of neonatal onset seizures and hypotonia. Pediatr Neurol 2015;52(5):354-43. [PubMed | CrossRef]

7. Konkoľová J, Petrovič R, Chandoga J, Repíšký M, Zelinková H, Kršiaková I, et al. Peroxisomal D-bifunctional protein deficiency: first case reports from Slovakia. Gene 2015;568(1):61-8. [PubMed | CrossRef]

8. Ghirri P, Vuercich M, Ferdinandusse S, Waterham HR, Guzzetta A, Bianchi MC, et al. A case of D-bifunctional protein deficiency: clinical, biochemical and molecular investigations. Pediatr Int 2011;53(4):583-7. [PubMed | CrossRef]

9. Incecik F, Mungan NO. D-bifunctional protein deficiency: a case report of a Turkish child. Ann Indian Acad Neurol 2019;22(1):119-21. [PubMed | CrossRef]

10. Khromykh A, Solomon BD, Bodian DL, Leon EL, Iyer RK, Baker RL, et al. Diagnosis of D-bifunctional protein deficiency through whole-genome sequencing: implications for cost-effective care. Mol Syndromol 2015;6(3):141-6. [PubMed | CrossRef]

11. McMillan HJ, Worthylake T, Schwartzentruber J, Gottlieb CC, Lawrence SE, Mackenzie A, et al. Specific combination of compound heterozygous mutations in 17β-hydroxysteroid dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional protein deficiency. Orphanet J Rare Dis 2012;7(1):90. [PubMed | CrossRef]

12. Farkas A, Al-Ramadhani R, McDonald K, Jordan M, Joyner D. Unusual Clinical course and imaging of D-bifunctional protein deficiency, a rare leukodystrophy. Pediatr Neurol 2019;90:70-1. [PubMed | CrossRef]

13. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86(5):749-64. [PubMed | CrossRef]

14. Vasudevan P, Suri M. A clinical approach to developmental delay and intellectual disability. Clin Med (Lond) 2017;17(6):558-61. [PubMed | CrossRef]

15. van Karnebeek CD, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab 2012;105(3):368-81. [PubMed | CrossRef]

16. Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E, et al. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genet Med 2017;19(1):121-6. [PubMed | CrossRef]

17. Paker AM, Sunness JS, Breteon NH, Speed JI, Albanna L, Dharmaraj S, et al. Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial. Neurology 2010;75(9):826-30. [PubMed | CrossRef]